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Purpose: To identify the solute carrier family 4 (sodium borate cotransporter) member 11 (SLC4A11) mutation spectrum
and to perform genotype-phenotype correlations in autosomal recessive Congenital Hereditary Endothelial Dystrophy
(CHED2) in North Indian patients.
Methods: Twenty-five patients from twenty families clinically diagnosed with autosomal recessive CHED2 were recruited
for the study. Clinical parameters such as age at onset, presentation, and pre- and post-operative visual acuities were
recorded. Corneal buttons of patients undergoing keratoplasty were analyzed for histopathologic and ultrastructural
confirmation. All the affected individuals and 50 unrelated population matched normal controls were screened for
underlying sequence changes. Genomic DNA was isolated from peripheral blood samples and all the exons and the 5′-
upstream region of the SLC4A11 gene were screened for mutations by direct DNA sequencing.
Results: A high degree of consanguinity (9 out of 20 families) was noted. Corneal haze was reported to be present since
birth or shortly thereafter in all affected patients. Histology and electron microscopy studies revealed increased thickness
of Descemet’s membrane, especially of the non-banded zone. Molecular studies revealed one novel homozygous in-frame
deletion mutation in two affected siblings from one family and three other previously reported homozygous mutations in
12 patients from 9 families. Mutations were not identified in 11 patients from 11 families. High interfamilial and
intrafamilial phenotypic variability was seen among the cohort of patients.
Conclusions: This is the first report on the mutation spectrum and genotype-phenotype correlation in CHED2 patients
from North India. The present study detected one novel and three reported changes, adding to the repertoire of mutations
in SLC4A11, and recorded a high degree of genetic heterogeneity in CHED2.
Congenital hereditary endothelial dystrophy (CHED) is
defined  as  a  rare  inheritable  disorder  of  the  corneal
endothelium  characterized  by  bilateral,  symmetric,  non-
inflammatory corneal clouding (edema) seen at the time of
birth or shortly thereafter [1]. The degeneration of the corneal
endothelium leads to corneal edema, especially of the stroma,
and gives the cornea an appearance resembling ground glass.
Two subtypes of CHED are known – autosomal dominant
(CHED1; OMIM 121700) and autosomal recessive (CHED2;
OMIM  217700)  –  based  on  differences  in  the  mode  of
inheritance  [2].  Clinically,  both  forms  have  similar
presentation, the latter being more severe. Different loci have
been mapped to 20p11.2-q11.2 [3] and 20p13, for CHED1 and
CHED2, respectively [4].
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The Solute Carrier family 4 (sodium borate cotransporter)
member 11 (SLC4A11; OMIM 610206) has been identified as
the candidate gene for CHED2 [5]. This gene has 19 exons
that  encode  the  bicarbonate  transporter–related  protein  1
(BTR1) of 891 amino acids and 14 transmembrane domains
with  intracellular  amino  and  carboxyl  terminals.  Several
functions have been defined for BTR1; the important ones are
its role in maintenance of boron homeostasis, cell growth and
proliferation, and activation of the mitogen-activated protein
kinase pathway [6]. Vithana et al. [5] hypothesized that a
deregulation of the mitogen-activated protein kinase pathway
and a failure of the mutant protein to reach the cell surface to
perform its function leads to the symptoms of CHED2 [5].
Mutations in SLC4A11 are described in Harboyan syndrome,
also known as Corneal Dystrophy and Perceptive Deafness
(CDPD; OMIM 217400), which is characterized as CHED2
with hearing loss [7].
Several studies have been performed to analyze the role
of this gene in causation of CHED2, which involves mainly
patients from South India [8-10]. There are no published data
Molecular Vision 2010; 16:2955-2963 <http://www.molvis.org/molvis/v16/a318>
Received 1 September 2010 | Accepted 23 December 2010 | Published 31 December 2010
© 2010 Molecular Vision
2955available  from  the  Northern  part  of  India.  Therefore,  the
present study was undertaken to assess the role of SLC4A11
in the pathogenesis of CHED2 in North Indian patients.
METHODS
The study protocol adhered to the tenets of Declaration of
Helsinki  and  the  Institutional  Ethics  Committee  provided
ethical approval for the study. In total, 25 patients from 20
families diagnosed with CHED2 were included in the study.
Corneal dystrophy was diagnosed on clinical examination.
Detailed family histories were collected and pedigree charts
were  constructed  for  all  of  the  patients;  the  presence  of
consanguinity was noted based on marriage histories.
Clinical  studies:  The  clinical  examination  included
routine  slit  lamp  biomicroscopy,  confocal  microscopy,
specular  microscopy,  ultrasonic  pachymetry,  orbscan,  and
ultrasonography  (USG)  for  posterior  segment  evaluation.
Patients who were bilaterally affected and without any other
systemic involvement formed the study group. The diagnosis
of  CHED  was  made  on  the  basis  of  the  following
characteristics: presence of mosaic corneal haze with corneal
edema, increased central corneal thickness (>0.7 mm in all
cases), normal horizontal corneal diameter (10–11 mm), and
no evidence of congenital glaucoma (e.g., no buphthalmos,
Haab’s striae, or optic disc cupping).
The control population consisted of 50 healthy, unrelated,
population-matched individuals who had no history of any
ocular disease in their family.
Histological  studies:  Histopathology  and  electron
microscopic  (EM)  studies  were  performed  on  7  corneal
buttons obtained from 7 patients after penetrating keratoplasty
surgery. Each corneal button was divided in half; one half was
used for histopathology (fixed in 10% buffered formalin) and
the other half for electron microscopic (EM) studies.
For histopathological studies, the formalin-fixed corneal
tissue samples from 7 patients were embedded in paraffin
blocks  and  cut  into  4  μM  thick  sections.  Sections  were
analyzed by light microscopy after staining with hematoxylin
and eosin (H&E), periodic acid Schiff, and Congo red dyes.
Ultrastructural  analysis:  The  corneal  tissues  were
collected  from  five  patients  at  the  time  of  penetrating
keratoplasty and immediately fixed in Karnovski fixative.
Two  corneal  tissue  samples  could  not  be  processed  for
transmission  electron  microscopy  as  the  patients  had
undergone keratoplasty 8 years previously.
After the dehydration and clearing processes, the tissue
samples were embedded in araldite blocks. Sections were cut
with an ultramicrotome (UC-6; Leica; Lab India, New Delhi,
India) using a glass knife and the electron micrographs were
taken with an electron microscope (MORGAGNI 268D; FEI,
Eindhoven, The Netherlands).
Genetic analysis: A 5 ml sample of peripheral blood was
collected by venipuncture in EDTA from all patients and
controls  after  taking  informed  consent  from  all  of  the
participants. Genomic DNA was extracted by the salting out
method [11].
The DNA was amplified in a thermocycler (ABI 9700;
Applied Biosystems [ABI], Foster City, CA) by PCR using
the  primers  as  described  previously  (Table  1)  [5].  The
amplification  reaction  mixture  consisted  of  10  ng  DNA,
1.5 mM MgCl2, 0.25 mM of each dNTP, 10pM of each primer,
and 0.7 units of Taq polymerase (Roche, ABI, Foster City,
CA), and Q-sol (Qiagen GmBH, Hilden, Germany) in a total
volume of 25 μl. The amplified PCR products were subjected
to gel purification using QIAmp gel extraction kits (Qiagen
GmBH) and the purified PCR products were screened for
sequence changes by bidirectional sequencing. The amplified
products were sequenced directly with BigDye Terminator
Mix  version  3.1  (ABI)  according  to  the  manufacturer’s
instructions and were then analyzed on an ABI-3100 Genetic
Analyzer (ABI). Nucleotide sequences for the coding regions
were compared with the nucleotide sequence of the published
SLC4A11 human cDNA (NM_032034). The families that did
not show SLC4A11 coding region changes were screened for
mutations  in  the  putative  promoter  region  using  primers
described earlier [8].
One family was screened for underlying changes in the
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6
(CHST6; OMIM 605294) gene as the mother was suspected
to have macular corneal dystrophy based on her phenotypic
presentation. PCR amplification was done using the primers
as described previously (Table 1) [12] in a reaction mixture
consisting of 100 ng DNA, 1.5 mM MgCl2, 0.25 mM of each
dNTP, 10pM of each primer, and 1.0 units of Taq polymerase
(Roche, ABI), and Q-sol (Qiagen GmBH) in a total volume
of 25 μl.
Polyphen  2  and  SIFT  analysis:  The  PolyPhen  2  and
SIFT (Sorting Intolerant From Tolerant) tools were used for
analysis of novel mutations to characterize the pathogenic
nature of the identified changes. The SIFT tool generates
multiple sequence alignments of a gene over different species
and assesses the degree of conservation of the substituted
positions over the course of evolution. It gives a value as a
score,  where  a  score  <0.05  is  considered  to  represent  a
potentially damaging mutation.
RESULTS
Several  clinical  parameters  were  assessed  to  confirm
autosomal recessive CHED2 in the patients forming the study
group.
Clinical  examinations:  Corneal  pachymetry  revealed
increased corneal thickness in all the cases. The age of the
patients ranged from 4 to 34 years (Table 2). The intraocular
pressure was within normal range (below 21 mmHg) for all
patients. Nystagmus was present in 19 patients and 38 eyes.
A high degree of consanguinity (9 out of 20 families) was
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2956noted among the CHED2 patients. Corneal haze was reported
to have been present since birth or shortly thereafter in all the
cases.  Clinical  examinations  (slit  lamp  biomicroscopy)  of
parents  (thirty  parents  from  seventeen  families)  revealed
unaffected clear corneas. None of the patients in the present
study group had associated sensorineural hearing loss.
Light  microscopy  analysis:  Histopathological
examination  for  the  patients  undergoing  keratoplasty
confirmed the diagnosis of CHED2 in all of the patients. Light
microscopy  revealed  widening  of  the  stroma  and  marked
thickening  of  Descemet’s  membrane.  Few  atrophic
endothelial cells could be identified in two cases, whereas the
rest  of  the  corneal  tissues  had  completely  atrophied
endothelium (Table 2).
Ultrastructural  analysis:  Electron  microscopy  (EM)
revealed  degeneration  of  keratocytes.  Fragmentation  and
disorganization  of  collagen  fibers  was  seen,  leading  to
separation of collagen lamellae. An overall increase in stromal
thickness  was  observed,  with  the  presence  of  numerous
vacuoles or water clefts in the stroma. The most conspicuous
observation  was  an  increase  in  the  total  thickness  of  the
Descemet’s membrane, which was due to an increase in the
thickness of the non-banded zone (5–8 times thicker than the
normal);  the  banded  zone  had  normal  thickness  and
morphology. The non-banded zone had numerous collagen
bundles, but no endothelial cells were observed, indicating
almost complete absence and attenuation of the endothelium.
These findings were similar for all of the CHED2 patients, in
whom the ultrastructural imaging was done, confirming the
clinical diagnosis.
Mutation  analysis:  Direct  DNA  sequence  analysis
showed 14 CHED2 patients from 9 families had underlying
SLC4A11  mutations  that  co-segregated  with  the  disease
phenotype and which were absent in 50 population matched
controls.
A novel in-frame homozygous deletion mutation of one
of the four leucine residues c2518-c2520 del CTG in exon 18
was seen in two affected siblings of a family (Figure 1A) who
also had associated spheroidal degeneration (Figure 1B). The
presence  of  mutation  was  confirmed  on  bidirectional
sequencing in both the siblings (Figure 1C). Conservation of
the  amino  acid  residues  involved  in  the  novel  deletion
mutations is shown in Figure 1D. Ultrastructural studies of the
proband carrying the novel mutation revealed the presence of
large  vacuoles  in  the  stromal  keratocytes  and  a  marked
increase in the thickness of the Descemet’s membrane (Figure
1E-G).
Other  mutations  documented  in  the  study  included  a
homozygous missense mutation c.2470G>A in exon 18 in 6
affected patients from 4 families (Figure 2A). A homozygous
missense mutation, c.1156T>C, was seen in three affected
individuals  from  2  families  that  led  to  substitution  of  a
cysteine residue at amino acid position 386 with arginine
(C386R;  Figure  2B).  Both  of  these  mutations  have  been
reported in patients from South India. A splice site mutation
c.2240+1G>A was seen in a family that showed a variable
phenotype (Figure 2C). Apart from these, two homozygous
changes in introns 2 and 11 were identified in two patients
from two families, respectively, but no coding region changes,
either heterozygous or homozygous, were seen in them. No
TABLE 1. TABLE SHOWING PRIMER SEQUENCES AND PCR CONDITIONS USED FOR AMPLIFICATION OF SLC4A11 AND CHST6 GENES.
SLC4A11 gene
  Primer Sequence 5′to 3′  
Exons
Forward Reverse
Annealing
temperature (°C)
1 CCTAGCAGATGGGCTAAGCA GAGCAAAGCCACAGGACTCT 60
2 and 3 CGAGAGTGGGACAGTCCAG CTCCCTGTTGAGTGCTCCT 62
4 and 5 TCCAGGAGCAGCTCAACAG CAGCCCTCTTCTCCCAAGTT 57
6 CCAACCAACTTGGGAGAAGA CCTTCAGAGGCCAGGACAT 52
7 and 8 AAAACCTGCTGCCAGTTCAT CCTAGGAATGGGGGATGG 57
9 and 10 ACTGATGGTACGTGGCCTCT CGTCCATGCGTAGAAGGAGT 58
11 and 12 TCTACATCCAGGGTGCAGTG CGTCCATGCGTAGAAGGAGT 56
13 and 14 GAGCCCTTTCTCCCTGAGAT GGTTGTAGCGGAACTTGCTC 61
15 and 16 CGGGAAATCGAGAGTGAGTT CGTCTCCTTCACGTTCACAA 54
17 and 18 CTGGCCACATGGGACATAG CTAGGCAGGACCCCTCCTC 53.5
19 CAGGAGGGGCTCCAGTCTA CTGTCCCTTGCATTCCACTT 55
Putative Promoter
region 1
GCCTTACTCACCCAATCTATGC CCCTGTCTCCTCCTTTCGAC 61
Putative Promoter
region 2
GGAGGAGGAGAAGGACTTGC GCACACTCGCGCACTCAC 55
CHST6 gene
  Primer Sequence 5′to 3′  
Coding region Reverse Annealing
temperature (°C)
1 GCCCCTAACCGCTGCGCTCTC- GGCTTGCACACGGCCTCGCT 57
2 GACGTGTTTGATGCCTATCTGCCTTG- CGGCGCGCACCAGGTCCA 55
3 CTCCCGGGAGCAGACAGCCAA CTCCCGGGCCTAGCGCCT 57
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2958other coding region variations were identified in 11 patients
from  11  families.  In  addition,  screening  of  the  upstream
putative promoter region also failed to reveal any change in
these 11 individuals.
Details of the family (Q1) with a variable phenotypic
presentation and a splice site mutation c.2240+1G>A: The
proband, a 20 year old male (Figure 3A), presented with
bilateral ground glass cornea with bullae. Corneal cloudiness
and nystagmus were reported to have been present right from
birth  (Figure  3B,C).  Family  history  revealed  parental
consanguinity and one more affected sibling. Visual acuity of
the proband was counting fingers from a 1 m distance in the
right eye and counting fingers close to the face in the left eye.
Corneal pachymetry revealed increased corneal thickness that
was  beyond  the  measurement  limits  of  the  specular
microscope.  Molecular  analysis  identified  a  homozygous
splice site mutation c.2240+1G>A.
Histopathological  analysis  identified  a  markedly
thickened  Descemet’s  membrane  and  an  atrophied
endothelium,  confirming  the  diagnosis  of  CHED2.
Additionally, the patient’s cornea also had amyloid deposition
and spheroidal degeneration. The presence of amyloid was
confirmed based on the presence of apple green birefringence
when viewed under a polarizing filter (Figure 3D).
The affected sibling, i.e., a younger sister of the proband,
was also examined. She was 15 years old, with cloudy corneas
since birth, but no nystagmus. Bilateral diffuse limbus-to-
limbus  stromal  haze  with  stromal  thickening  and  guttae
changes was seen (Figure 3E). Vision in both eyes was limited
to counting fingers from 1 m. Corneal pachymetry revealed
an increased corneal thickness (right eye- 980, left eye-1010).
Molecular  analysis  identified  a  homozygous  splice  site
mutation  c.2240+1G>A.  None  of  the  unaffected  siblings
showed the mutation in either homozygous or heterozygous
state.
The 60-year-old mother was also clinically examined and
she reported to have had a history of bilateral lime injury
during  childhood.  Defective  vision,  photophobia,  and
Figure 1. Genotype-phenotype features of the novel SLC4A11 deletion mutation. A: Pedigree of the family showing a novel deletion mutation
of one of the four leucine residues c2518-c2520 del CTG in the exon 18 of Solute Carrier Family 4 (sodium borate co-transporter) member
11 (SLC4A11). Filled boxes represent affected individuals. Open boxes represent unaffected individuals. Arrow indicates the proband. B: Slit
lamp photomicrographs of the affected individual harboring the novel mutation. The representative clinical photograph shows the presence
of marked stromal haze and spheroidal degeneration in the right eye of the proband. C: Partial nucleotide sequence of SLC4A11. The
chromatogram of the patient (P) is shown in comparison to control (C). The block marks the four CTG repeats in the control and only three
in the patient. The homozygous deletion of CTG residue in the patient can be noted. D: Multiple sequence alignment of SLC4A11 gene from
different species. The amino acid leucine (L) at positions 840–843 is conserved over a range of species in the course of evolution, which are
highlighted in red. E: Transmission electron micrographs of the affected patient harboring the novel mutation. E: Transmission electron
micrograph showing Descemet’s membrane of the CHED2 patient. Descemet’s membrane is thickened, with a normal anterior banded zone
and a thickened posterior banded layer (Scale bar 2 μm). F: This panel represents a magnified view of part of the posterior banded layer
showing presence of thick collagen bundles indicated by the arrows. G: The disorganized corneal stroma can be noted along with the presence
of amorphous material. (Scale bar 2 μm).
Molecular Vision 2010; 16:2955-2963 <http://www.molvis.org/molvis/v16/a318> © 2010 Molecular Vision
2959watering had been present for the past 15 years (Figure 3F).
Vision in the right eye was recorded as counting fingers from
1 m distance and the left eye had vision restricted to counting
fingers  close  to  the  face.  Corneal  pachymetry  revealed  a
normal  corneal  thickness  (right  eye-524µm  and  left
eye-527 µm) but bilateral endothelial opacities and stromal
haze were noted. Additionally, a few epithelial opacities were
seen. The phenotype of the mother resembled macular corneal
dystrophy  with  epithelial  and  endothelial  involvement.
Mutation  analysis  identified  the  heterozygous  splice  site
mutation c.2240+1G>A. No other changes were noted in the
coding  region,  overlapping  splice  sites,  and  the  putative
promoter region of SLC4A11.
In view of the different clinical presentation seen in the
mother,  who  resembled  macular  corneal  dystrophy,  the
affected family members were screened for mutations in the
CHST6  gene,  which  are  known  to  cause  macular  corneal
dystrophy. No coding region changes were seen in CHST6,
either in the mother or in any of her affected offspring.
DISCUSSION
The SLC4A11 gene codes for BTR1 that functions as a sodium
borate co-transporter (NaBC1) and plays a role in activation
of  the  mitogen  activated  protein  kinase  pathway  [6].
Mutations in the SLC4A11 gene lead to nonsense mediated
mRNA decay or formation of a truncated protein that is unable
to  reach  the  surface  and  perform  its  function.  It  is  the
Figure  2.  Mutations  in  SLC4A11
causing CHED2. A: Partial nucleotide
sequence  SLC4A11.  The
chromatograms of the patients (P) are
shown in comparison to controls (C).
The homozygous G >A substitution is
marked by the block. The block denotes
the nucleotide with a missense mutation
resulting in amino acid substitution of
valine at amino acid position 824 with
methionine. B: The homozygous T>C
substitution is marked by the block. The
block  denotes  the  nucleotide  with  a
missense  mutation  resulting  in  amino
acid substitution of cysteine at amino
acid position 386 with arginine. C: The
homozygous  G>A  substitution  is
marked by the block. The block denotes
the nucleotide with a missense mutation
resulting  in  a  splice  site  mutation  c.
2240+1G>A.
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2960subsequent deregulation of the MAPKinase pathway that is
thought to cause CHED2.
In the present study we identified a novel c2518-c2520
delCTG mutation and assessed its pathogenic nature using
SIFT and PolyPhen 2 tools. The deleted leucine residue lies
in the transmembrane domain 11 and in silico analysis showed
that  the  leucine  residues  at  all  the  positions  in  the
transmembrane  domain,  ranging  from  840  to  843,  are
conserved over a wide range of species. Deletion of any one
of them can disrupt the appropriate assembly or localization
of the protein within the membrane. This may consequently
have lead to CHED2 in the two siblings, although the exact
mechanism remains unknown.
The  splice  site  mutation  c.2240+1G>A,  identified  in
family Q1 with CHED2 affects the first nucleotide of the
splice donor site and may probably cause mis-splicing of the
pre-mRNA  transcript.  This  would  lead  to  either,  exon
skipping or intron retention, which would consequently result
in  an  altered  protein  structure.  However,  it  is  difficult  to
determine the exact nature of the mis-splicing and the fate of
the mutant transcripts, due to non-expression of SLC4A11 in
lymphocytes [13]. Gene expression studies to determine the
nature and variable expression of SLC4A11 would require
corneal tissue of heterozygous individuals, which was not
possible in the present study.
The  most  interesting  feature  of  family  Q1  was  the
intrafamilial variability with presence of variable phenotypes
in the affected siblings who were homozygous for the splice
site  mutation  and  a  completely  different  phenotypic
presentation in the mother who was a heterozygous carrier.
Other family members who were heterozygous carriers of the
same mutation were unaffected and had clear corneas. The
mutation  c.2240+1G>A  has  been  reported  as  the  single
heterozygous change leading to CHED2 in a British white
(Caucasian) from the UK (UK), while the same change was
not observed in 30 South Indian and 50 European controls of
the study [13]. Similarly, in the present study, this change was
not  seen  in  the  50  controls  also  screened  for  SLC4A11
mutations. The reason for the presence of corneal opacities in
some heterozygous carriers and not in others is not clear. The
most plausible explanation could be that it is an autosomal
dominant change with variable penetrance and expressivity.
This change could also be described as a rare polymorphism
segregating  with  the  disease  phenotype  in  the  family.
However  presence  of  the  same  change  in  heterozygous
condition in a CHED2 patient of British origin is suggestive
of it being a pathogenic mutation.
Other  previously  reported  mutations  that  were  seen
included c.2470G>A in 6 affected patients from 4 families and
c.1156T>C in 3 affected individuals from 2 families. Both the
Figure 3. Family Q1 showing variable phenotype. A: Pedigree of the family showing the splice site mutation c.2240+1G>A and variable
phenotypic presentation of the affected members. Filled boxes represent affected individuals. Open boxes represent unaffected individuals.
Arrow indicates the proband. A double line indicates presence of consanguinity in the family. B, C: Representative slit lamp photomicrographs
of the proband with a homozygous splice site mutation c.2240+1G>A. The representative clinical photographs of right (B) and left eye (C)
of the proband shows the presence of the typical ground glass appearance of the cornea seen in autosomal recessive CHED. D: shows the
presence of apple green birefringence on staining with Congo-red and viewing under polarized filter, marked by arrows. E: The slit lamp
photomicrograph of the right eye of the affected sibling had marked stromal haze. F: The clinical photomicrograph of the mother shows the
endothelial deposits (marked by arrows) with stromal haze. A few epithelial deposits are also seen.
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2961mutations showed interfamilial and/or intrafamilial variability
and  no  genotype-phenotype  correlation  was  seen.  Similar
studies from South India have also reported absence of evident
correlations between clinical and histopathologic findings,
and SLC4A11 mutations [9,14]. These reports implicate that
phenotype presentation depends not only on the underlying
mutation but also involves role of other genes, developmental
and/or environmental factors.
In the present study, mutations were seen in 14 affected
individuals from 9 families in a cohort of 25 patients. Several
reports have been published describing the role of SLC4A11
mutations  in  the  causation  of  dystrophies.  In  reports  by
Sultana et al. [9], Jiao et al. [10], and Hemadevi et al. [8],
mutations  in  SLC4A11  were  identified  in  35  of  42  (83
percent), 12 of 16 (75 percent), and 11 of 20 (55 percent)
CHED2  families  screened.  These  studies  involved  Indian
patients, but most of them were from South India. We found
mutations in 14 of 25 (56 percent) patients diagnosed with
CHED2 in North India. A decrease in the number of patients
with underlying mutations in SLC4A11 in North India can be
due to the difference in origin of these two populations and a
relatively low rate of consanguinity in the Northern part as
compared to South. The disease, being autosomal recessive,
is associated with a high rate of consanguinity and thus is seen
to occur at a higher frequency in the South Indian population.
Cases of CDPD are reported to have SLC4A11 mutations
that result in an alteration of gene expression in the stria
vascularis causing impairment in the hearing efficiency of
these individuals [7]. However none of the patients in the
present study group had associated sensorineural hearing loss.
Heterozygous changes in SLC4A11 have been reported
in cases of late onset Fuchs endothelial corneal dystrophy
(FECD;  OMIM  136800)  in  which  haploinsufficiency  and
accumulation of aberrantly folded protein is reported to result
in FECD pathology [15]. The onset of symptoms for CHED2
and FECD are different, yet they share a common feature of
an abnormal posterior non-banded zone of the Descemet’s
membrane which points to endothelial dysfunction starting in
the late prenatal period [16]. In view of this, the parents of the
affected patients, who were identified as heterozygous carriers
of the SLC4A11 changes were clinically examined by slit lamp
biomicroscopy.  No  signs  and  symptoms  of  FECD  or
associated guttae changes were seen in any of the parents
examined, whose age range varied from 45 to 72 years.
Posterior  Polymorphous  Corneal  Dystrophy  (PPCD;
OMIM  122000)  is  another  dystrophy  which  results  from
primary endothelial dysfunction inherited as a dominant trait.
Incomplete  penetrance  and  de  novo  mutations  have  been
observed in PPCD cases with identified zinc finger E-box
binding homeobox 1(ZEB1; OMIM 189909) mutations which
can  lead  to  consideration  of  recessive  inheritance.  A  few
PPCD cases have been reported to present with corneal haze
at birth [16] which might result in an overlap in phenotypic
presentation of CHED and PPCD. Considering this, CHED2
cases with no SLC4A11 coding region changes should be
screened for mutations in ZEB1.
The  studies  on  endothelial  dystrophies  i.e.,  CHED,
FECD, and PPCD suggest that all these forms can actually be
allelic variants of the same disease continuum and that genetic
interaction between genes that cause corneal dystrophies can
modulate the expressivity of the phenotype [17]. Moreover,
they  all  are  considered  to  represent  defects  of  terminal
differentiation of the neural crest cells [17] and share common
features of disease manifestation like endothelial metaplasia,
and secretion of an abnormal Descemet’s membrane [17].
Considering  this  variability  in  expression,  all  cases  of
endothelial dystrophies should be screened for the presence
of  SLC4A11  and/or  ZEB1  changes  for  confirmation  and
categorization.
In conclusion, to the best of our knowledge, this is the
first report of mutation screening for the SLC4A11 gene in
CHED2 cases from North India. We identified 1 novel and 3
previously  reported  mutations  in  14  individuals  from  9
families and documented inter- and intrafamilial variability,
apart from the presence of genetic heterogeneity in our cohort
of patients.
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